Firstly, a study of Hemminki and colleagues has shown a clear anti-angiogenic effect using vvdd-VEGFR-1-Ig, an engineered VV targeted against kidney tumor cells that is armed with VEGFR-1-Ig. This evidence concerns the gene FLT1 and kidney neoplasm.